Clarity Pharmaceuticals: Pioneering Precision Diagnostics in Neuroendocrine Tumours

Clarity Pharmaceuticals (ASX:CU6), a clinical-stage radiopharmaceutical firm, recently announced promising Phase II results from its DISCO trial evaluating ⁶⁴Cu-SARTATE in diagnosing neuroendocrine tumours (NETs). The trial demonstrated that ⁶⁴Cu-SARTATE significantly outperformed the current standard-of-care imaging agent, ⁶⁸Ga-DOTATATE, by detecting nearly double the number of lesions and achieving a lesion-level sensitivity of up to 95.6%. The agent also proved safe, with no serious adverse events reported. Due to its favourable biodistribution and longer half-life, ⁶⁴Cu-SARTATE allowed for high-contrast imaging up to 24 hours post-injection, offering greater scheduling flexibility and detection accuracy. These results pave the way for a Phase III registrational trial with the U.S. FDA. Clarity sees a broader potential for this technology in other SSTR2-expressing cancers like breast and lung cancer, positioning ⁶⁴Cu-SARTATE as a transformative diagnostic solution in oncology.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com